These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. Zhuang L; Wai JS; Embrey MW; Fisher TE; Egbertson MS; Payne LS; Guare JP; Vacca JP; Hazuda DJ; Felock PJ; Wolfe AL; Stillmock KA; Witmer MV; Moyer G; Schleif WA; Gabryelski LJ; Leonard YM; Lynch JJ; Michelson SR; Young SD J Med Chem; 2003 Feb; 46(4):453-6. PubMed ID: 12570367 [TBL] [Abstract][Full Text] [Related]
7. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. Pace P; Di Francesco ME; Gardelli C; Harper S; Muraglia E; Nizi E; Orvieto F; Petrocchi A; Poma M; Rowley M; Scarpelli R; Laufer R; Gonzalez Paz O; Monteagudo E; Bonelli F; Hazuda D; Stillmock KA; Summa V J Med Chem; 2007 May; 50(9):2225-39. PubMed ID: 17428043 [TBL] [Abstract][Full Text] [Related]
8. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684 [TBL] [Abstract][Full Text] [Related]
9. 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. Summa V; Petrocchi A; Matassa VG; Gardelli C; Muraglia E; Rowley M; Paz OG; Laufer R; Monteagudo E; Pace P J Med Chem; 2006 Nov; 49(23):6646-9. PubMed ID: 17154493 [TBL] [Abstract][Full Text] [Related]
10. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. Gardelli C; Nizi E; Muraglia E; Crescenzi B; Ferrara M; Orvieto F; Pace P; Pescatore G; Poma M; Ferreira Mdel R; Scarpelli R; Homnick CF; Ikemoto N; Alfieri A; Verdirame M; Bonelli F; Paz OG; Taliani M; Monteagudo E; Pesci S; Laufer R; Felock P; Stillmock KA; Hazuda D; Rowley M; Summa V J Med Chem; 2007 Oct; 50(20):4953-75. PubMed ID: 17824681 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors. Johnson TW; Tanis SP; Butler SL; Dalvie D; Delisle DM; Dress KR; Flahive EJ; Hu Q; Kuehler JE; Kuki A; Liu W; McClellan GA; Peng Q; Plewe MB; Richardson PF; Smith GL; Solowiej J; Tran KT; Wang H; Yu X; Zhang J; Zhu H J Med Chem; 2011 May; 54(9):3393-417. PubMed ID: 21446745 [TBL] [Abstract][Full Text] [Related]
12. A potent and orally active HIV-1 integrase inhibitor. Egbertson MS; Moritz HM; Melamed JY; Han W; Perlow DS; Kuo MS; Embrey M; Vacca JP; Zrada MM; Cortes AR; Wallace A; Leonard Y; Hazuda DJ; Miller MD; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Gabryelski LJ; Moyer G; Ellis JD; Jin L; Xu W; Braun MP; Kassahun K; Tsou NN; Young SD Bioorg Med Chem Lett; 2007 Mar; 17(5):1392-8. PubMed ID: 17194584 [TBL] [Abstract][Full Text] [Related]
13. 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors. Nagasawa JY; Song J; Chen H; Kim HW; Blazel J; Ouk S; Groschel B; Borges V; Ong V; Yeh LT; Girardet JL; Vernier JM; Raney AK; Pinkerton AB Bioorg Med Chem Lett; 2011 Jan; 21(2):760-3. PubMed ID: 21185178 [TBL] [Abstract][Full Text] [Related]
14. 5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors. Peese KM; Allard CW; Connolly T; Johnson BL; Li C; Patel M; Sorensen ME; Walker MA; Meanwell NA; McAuliffe B; Minassian B; Krystal M; Parker DD; Lewis HA; Kish K; Zhang P; Nolte RT; Simmermacher J; Jenkins S; Cianci C; Naidu BN J Med Chem; 2019 Feb; 62(3):1348-1361. PubMed ID: 30609350 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors. Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751 [TBL] [Abstract][Full Text] [Related]
16. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. Zeng LF; Wang Y; Kazemi R; Xu S; Xu ZL; Sanchez TW; Yang LM; Debnath B; Odde S; Xie H; Zheng YT; Ding J; Neamati N; Long YQ J Med Chem; 2012 Nov; 55(22):9492-509. PubMed ID: 23098137 [TBL] [Abstract][Full Text] [Related]
18. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521 [TBL] [Abstract][Full Text] [Related]
19. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781 [TBL] [Abstract][Full Text] [Related]
20. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors. Ravichandran V; Shalini S; Sundram K; Sokkalingam AD Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]